Added to YB: 2025-06-10
Pitch date: 2025-06-08
1681.HK [neutral]
Consun Pharmaceutical Group Limited
+33.32%
current return
Author Info
Momentum Financial researches stocks from around the world to invest in for the long-term. Sign up for the newsletter.
Company Info
Consun Pharmaceutical Group Limited researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People’s Republic of China.
Market Cap
HKD 8.9B
Pitch Price
HKD 11.15
Price Target
N/A
Dividend
5.15%
EV/EBITDA
5.38
P/E
9.78
EV/Sales
1.88
Sector
Pharmaceuticals
Category
growth
Consun Pharma News - June 2025.
1681.HK (update): Consun Pharma's kidney disease focus aligns with WHO resolution. Key catalysts: Gadopentate (40% market share) entering centralized purchasing; State-protected Yishen Huashi (110M yuan, +27.2% YoY); SK-09 clinical trial approval for podocyte diseases; imaging contrast products with 60%+ margins despite price cuts.
Read full article (11 min)